Shares of Novocure (NVCR) are up over 28% at $22 in premarket trading, following positive regulatory news related to Optune Lua, a wearable cancer therapy system that delivers Tumor Treating Fields, or TTFields, therapy.
Optune Lua has received FDA approval for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progressed on or after a platinum-based regimen.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com